Aurinia Pharmaceuticals Inc (AUPH)
R&D Expense Growth
74.70%
Quarterly · Period ending:
AUPH R&D Expense Growth
Latest reported74.70%period ending
Latest reported74.70%period ending
AUPH Quarterly R&D Growth (QoQ) (0.00% → 74.70%)
Latest values, visible window
High-resolution chart · PNG
AUPH r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 74.6988% | |
| -31.4364% | |
| 29.1642% | |
| 13.4957% | |
| 29.4097% | |
| -29.16% | |
| 166.065% | |
| -25.3186% | |
| -26.4997% | |
| -45.7274% | |
| -24.8218% | |
| 7.5494% | |
| -3.8608% | |
| 33.3131% | |
| -10.0519% | |
| -4.7896% | |
| -8.6767% | |
| 13.194% | |
| -44.4384% | |
| 98.8505% | |
| 2.6238% | |
| -25.3549% | |
| 7.5962% | |
| 10.5363% | |
| -19.9422% | |
| 4.0852% | |
| -25.2881% | |
| 59.5319% | |
| 4.9008% | |
| -1.919% | |
| -2.8067% | |
| 6.1691% | |
| 18.1951% | |
| 2.2552% | |
| -19.5799% | |
| 52.0613% | |
| -2.9761% | |
| 34.1084% | |
| 63.4351% | |
| 38.9027% | |
| -27.6173% | |
| -8.9814% | |
| -21.7987% | |
| 7.8522% | |
| 30.03% | |
| 7.6973% | |
| 27.0859% | |
| -4.4759% | |
| 144.9038% | |
| 62.3506% | |
| 21.4741% | |
| 22.7551% | |
| 29.3161% | |
| -89.9385% | |
| 486.5902% | |
| -29.9278% | |
| -0.0717% | |
| -14.451% | |
| 26.4655% | |
| -33.3704% | |
| 38.7683% | |
| -17.023% | |
| 44.1882% | |
| -30.794% | |
| -30.231% | |
| -35.6007% | |
| 25.5468% | |
| 23.9832% | |
| -27.5953% | |
| 75.2857% | |
| -62.8667% | |
| -25.4696% | |
| 6.5069% | |
| -51.3348% | |
| 14.4125% | |
| -19.3396% | |
| 46.3355% | |
| 19.7264% | |
| -5.9867% | |
| 4.0597% | |
| 12.6232% | |
| -5.3969% | |
| -10.9667% | |
| 1.7317% | |
| 13.3922% | |
| -19.7942% | |
| 11.5034% | |
| 318.1131% | |
| -34.207% | |
| -43.178% | |
| 60.0691% | |
| 0.7904% | |
| 2.8666% | |
| 152.5862% | |
| -235.0736% | |
| -45.5386% | |
| 46.9888% | |
| 0% | |
| -35.6139% | |
| 58.9716% |